Microbiology programs
ADENOVIRUS SEROLOGY
Program: ADE: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative*
The scheme is intended for NovaLisa, Virion/Serion and Euroimmun ELISA reagents. Other reagents upon request.
Analytical parameters:
IgA, IgG and IgM antibodies against Adenovirus
ASPERGILLUS FUMIGATUS SEROLOGY
Program: ASF: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative*
The scheme is intended for Virion/Serion ELISA reagents. Other reagents upon request.
Analytical parameters:
IgA, IgG, IgM and total antibodies against Aspergillus fumigatus
ASPERGILLUS GALACTOMANNAN ANTIGEN
Program: ASPAG: 2 surveys/year x 2 samples
Material: Liquid samples of simulated bronchoalveolar lavage (BAL) fluid or serum (minimum 0,5 mL)
Evaluation: Qualitative and quantitative*
Analytical parameters:
Aspergillus Antigen (Galactomannan)
BACTERIOLOGY
Program: BAC-C or BAC-E: 4 surveys/year x 4 samples
Material: Lyophilised samples (pure strain and/or mixture of bacteria): 2 for identification and 2 for antibiotic
susceptibility testing (AST). AST according to EUCAST or CLSI guidelines.
In this program we simulate different types of specimens: blood, urine, swabs (e.g. surgical/wound site, etc.), sputum/bronchospcopy specimen, paracentesis samples (e.g. ascites), joint/synovial fluid, sonicate fluid of explanted prosthetic joints, and CSF.
Evaluation: Qualitative
Analytical parameters:
Identification (genus and species)
Antibiotic susceptibility testing (according to EUCAST or CLSI guidelines)
BACTERIOLOGY BLOOD CULTURE
Program: BACBC-C or BACBC-E: 4 surveys/year x 4 samples
Material: Lyophilised samples (pure strain and/or mixture of bacteria): 2 for identification and 2 for antibiotic
susceptibility testing (AST). AST according to EUCAST or CLSI guidelines.
In this program we simulate blood specimens focusing on blood culture pathogen identification and antimi- crobial susceptibility testing.
Evaluation: Qualitative
Analytical parameters:
Identification (genus and species)
Antibiotic susceptibility testing (according to EUCAST or CLSI guidelines)
BACTERIOLOGY URINE CULTURE
Program: BACUC-C or BACUC-E: 4 surveys/year x 2 samples
Material: Lyophilised samples (pure strain and/or mixture of bacteria): 1 for identification and 1 for antibiotic
susceptibility testing (AST). AST according to EUCAST or CLSI guidelines.
In this program we simulate urine specimens focusing on urine culture pathogen isolation, identification, and
antimicrobial susceptibility testing.
Evaluation: Qualitative
Analytical parameters:
Identification (genus and species)
Antibiotic susceptibility testing (according to EUCAST or CLSI guidelines)
BORDETELLA SEROLOGY
Program: BPES: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgA, IgG and IgM antibodies against Bordetella
IgA antibodies against Bordetella Pertussis-Toxin
IgG antibodies against Bordetella Pertussis-Toxin
BORRELIA SEROLOGY
Program: BOR: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
Material: One CSF/serum sample pair and (simulated) clinical information on the patient needed to calculate the antibody index is provided to the participant (CSF sample: 0,8 mL; serum sample: 0,3 mL)
Evaluation: Qualitative and quantitative
Material: One CSF/serum sample pair and (simulated) clinical information on the patient needed to calculate the antibody index is provided to the participant (CSF sample: 0,8 mL; serum sample: 0,3 mL)
Evaluation: Qualitative and quantitative
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
IgG and total antibodies against Trypanosoma cruzi (quantitative)
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Program: COX: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgA, IgG and IgM antibodies against Coxsackievirus
DENGUE VIRUS ANTIBODIES
Program: DENV: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
IgG and IgM antibodies against Dengue Virus
DENGUE VIRUS NS1 ANTIGEN
Program: DENVAG: 2 surveys/year x 2 samples
Material: Liquid or lyophilized samples. The samples are either serum or plasma samples or simulated samples consisting of an aqueous protein matrix. Dengue virus NS1 antigen positive samples contain recombinant DENV NS1 protein
Evaluation: Qualitative
Analytical parameters:
Dengue Virus NS1 antigen
ECHO VIRUS SEROLOGY
Program: ECH: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgA, IgG and IgM antibodies against ECHO-Virus
ENTEROVIRUS SEROLOGY
Program: ENT: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgA, IgG and IgM antibodies against Enterovirus
EPSTEIN-BARR VIRUS SEROLOGY
Program: EBV: 4 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
anti-EBV EBNA-1 IgG + total
anti-EBV VCA IgG + total
anti-EBV VCA IgM
HELICOBACTER PYLORI ANTIBODIES
Program: HPYL: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
IgA, IgG, IgM and total antibodies against Helicobacter pylori
HELICOBACTER PYLORI ANTIGEN
Program: HPYLAG: 2 surveys/year x 2 samples
Material: Liquid or simulated stool samples (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
Helicobacter pylori Antigen
HEPATITIS A VIRUS SEROLOGY
Program: HAV12: 12 surveys/year x 1 sample HAV4: 4 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgG, IgM and total antibodies against HAV
HEPATITIS B VIRUS SEROLOGY
Program: HAV12: 12 surveys/year x 1 sample HAV4: 4 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
anti-HBs
anti-HBc IgG + total
anti-HBe
anti-HBc IgM
HBsAg
HBeAg
HEPATITIS E VIRUS SEROLOGY
Program: HEV: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
IgG, IgM and total antibodies against HEV
HIV ANTIBODIES AND ANTIGEN
Program: HIV: 4 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
anti-HIV 1/2 antibodies
HIV p24 Antigen
HTLV I/II
Program: HTL: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
Total antibodies against HTLV I/II
INFECTIOUS DISEASE COMBINATION CONTROL SEROLOGY
Program:
INF12: 12 surveys/year x 1 sample
INF4: 4 surveys/year x 2 samples
INF4x4: 4 surveys/year x 4 samples
INF2: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 1 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
anti-HIV 1/2 / p24 Ag
anti-HCV
anti-HBc
HBsAg
INFLUENZA A VIRUS SEROLOGY
Program: INA: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgA, IgG and IgM antibodies against Influenza A Virus
INFLUENZA B VIRUS SEROLOGY
Program: INB: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgA, IgG and IgM antibodies against Influenza B Virus
LEGIONELLA PNEUMOPHILA ANTIBODIES
Program: LPAB: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgG, IgM and total antibodies against Legionella pneumophila
LEPTOSPIRA SEROLOGY
Program: LEP: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgG and IgM antibodies against Leptospira
MALARIA MICROSCOPY
Program: MALM: 4 surveys/year x 2 samples
Material: Slides of stained smears
Evaluation: Qualitative and quantitative
Analytical parameters:
Malaria Parasite Detection
Species Identification
Stage Identification
Quantification of Plasmodium falciparum
MEASLES SEROLOGY
Program: MEA: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
IgG and IgM antibodies against Measles Virus
MYCOPLASMA ANTIBODIES
Program: MYPL: 2 surveys/year x 2 samples
Material: Samples of human serum (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
IgA, IgG, IgM and total antibodies against Mycoplasma pneumoniae
PARAINFLUENZA VIRUS SEROLOGY
Program: PIN: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgA, IgG and IgM antibodies against Parainfluenza Virus
PARVOVIRUS B19 SEROLOGY
Program: PAR: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
IgG and IgM antibodies against Parvovirus B19
RESPIRATORY SYNCYTIAL VIRUS (RSV) SEROLOGY
Program: RSV: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgG, IgM and IgA antibodies against Respiratory Syncytial Virus (RSV)
RESPIRATORY VIRAL ANTIGEN DETECTION
Program: RESPAg: 2 surveys/year x 3 samples
Material: Lyophilized samples (minimum 0,3mL) simulating swab specimens (e.g. oropharyngeal,
nasopharyngeal, nasal etc.) or swabs. Antigen positive samples contain inactivated whole virus.
Evaluation: Qualitative
Analytical parameters:
Influenza A Antigen
Influenza B Antigen
RSV Antigen
SARS-CoV-2 ANTIGEN
Program: COVAG: 4 surveys/year x 3 samples
Material: Liquid or lyophilized samples simulating swab specimens (e.g. oropharyngeal, nasopharyngeal,
nasal etc.). SARS-CoV-2 antigen positive samples contain inactivated whole virus (minimum 0,3 mL).
Evaluation: Qualitative
Analytical parameters:
SARS-CoV-2 Antigen (qualitative)
SARS-CoV-2 SEROLOGY
Program: COVID: 2 Surveys/year x 4 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgA, IgG, IgM and total antibodies against SARS-CoV-2
SARS-CoV-2 neutralising antibodies
STREPTOCOCCUS A ANTIGEN
Program: STAA: 2 Surveys/year x 2 samples
Material: Swab, liquid or lyophilized samples (minimum 0,3 mL) simulating swab specimens.
Evaluation: Qualitative
Analytical parameters:
Streptococcus A Antigen
SYPHILIS SEROLOGY
Program:
SYP12: 12 surveys/year x 1 sample
SYP4: 4 surveys/year x 2 samples
SYP2: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (1 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
Total antibodies against Treponema pallidum (qualitative, semi-quantitative and quantitative)
IgG and IgM antibodies against Treponema pallidum (qualitative)
Non-treponemal Lipoid antibodies (RPR/VDRL Tests) (qualitative)
Non-treponemal Lipoid antibodies (RPR/VDRL Tests Titers) (semi-quantitative)
TBEV IgG ANTIBODY INDEX
Program: TBEV-G-AI: 2 surveys/year x 2 samples
Material: CSF/serum sample pair and (simulated) clinical information on the patient needed to calculate the antibody index is provided to the participant (CSF sample 0,8 mL; 0,3 mL for the serum sample)
Evaluation: Qualitative and quantitative
Analytical parameters:
TBEV IgG-antibody index (AI), qualitative and quantitative
TBEV IgM ANTIBODY INDEX
Program: TBEV-M-AI: 2 surveys/year x 2 samples
Material: CSF/serum sample pair and (simulated) clinical information on the patient needed to calculate the antibody index is provided to the participant (CSF sample 0,8 mL; 0,3 mL for the serum sample)
Evaluation: Qualitative and quantitative
Analytical parameters:
TBEV IgM-antibody index (AI), qualitative and quantitative
ToRCH SEROLOGY
Program:
TORCH12: 12 surveys/year x 1 sample
TORCH4: 4 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 1 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
anti-CMV IgG
anti-CMV IgM
anti-HSV 1/2 IgG
anti-HSV 1 IgG
anti-HSV 2 IgG
anti-HSV 1 IgM
anti-HSV 2 IgM
anti-HSV 1/2 IgM
anti-Rubella IgG
anti-Rubella IgM
anti-Toxoplasmose gondii IgG
anti-Toxoplasma gondii IgM
VARIZELLA ZOSTER VIRUS SEROLOGY
Program: VZV: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative and quantitative
Analytical parameters:
IgA, IgG, and IgM antibodies against Varizella Zoster Virus (VZV)
WEST NILE VIRUS SEROLOGY
Program: WNV: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
IgG and IgM antibodies against West Nile Virus
ZIKA VIRUS SEROLOGY
Program: ZIKV: 2 surveys/year x 2 samples
Material: Liquid samples of defibrinated human plasma (minimum 0,3 mL)
Evaluation: Qualitative
Analytical parameters:
IgG and IgM antibodies against Zika Virus